AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PRTA · NASDAQ · Biotechnology

Prothena (PRTA)

Develops investigational protein-dysregulation therapies with a partner-heavy clinical pipeline.

$8.71

vs last close−0.28 (−3.15%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	85	0	0	132	1	2	3	4	2	0	51	1
Cost of revenue	58	62	0	0	0	0	0	0	29	1	1	0
Gross profit	27	−62	0	132	1	2	3	4	−27	−1	50	1
	17	17	82	74	67	67	68	89	14	26	24	22
Research & development	58	62	64	58	51	50	51	41	29	15	13	9
	17	17	17	16	17	17	18	16	13	13	13	11
General & administrative	17	17	17	16	17	17	18	16	13	13	13	11
Other expenses	−58	−62	0	0	0	0	0	33	−28	−1	−1	2
Operating income	10	−79	−82	58	−67	−65	−66	−85	−40	−27	26	−21
	15	14	7	6	7	5	4	4	4	6	7	3
Interest income	9	8	7	7	7	5	4	4	3	3	2	3
Other non-operating income	0	−14	−7	−6	−7	−5	−4	−33	−4	−6	−7	−3
Income before tax	25	−64	−74	65	−60	−60	−61	−81	−36	−22	33	−19
Income tax expense	3	3	−2	−2	−1	−2	−1	45	0	0	0	0
Net income from continuing operations	22	−67	−72	67	−59	−58	−60	−126	−37	−22	33	−19
Net income	22	−67	−72	67	−59	−58	−60	−126	−37	−22	33	−19
EPS, basic	$0.41	−$1.26	−$1.34	$1.24	−$1.10	−$1.08	−$1.12	−$2.34	−$0.68	−$0.40	$0.61	−$0.36
EPS, diluted	$0.38	−$1.26	−$1.34	$1.22	−$1.10	−$1.08	−$1.12	−$2.34	−$0.68	−$0.40	$0.60	−$0.36
Weighted average shares, basic	54	54	54	54	54	54	54	54	54	54	54	52
Weighted average shares, diluted	58	54	54	55	54	54	54	54	54	54	54	52
EBITDA	11	−64	−74	65	−60	−59	−61	−52	−36	−21	34	−18
Depreciation & amortization	0	0	0	0	0	0	0	0	0	1	1	0
EBIT	10	−64	−74	65	−60	−60	−61	−52	−36	−22	33	−19